2019-04-10

Positive results for Buvidal® in treatment for fentanyl dependence

New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl abuse, among other things, compared to other standard treatments as well as lower withdrawal and drug craving.

New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl abuse, among other things, compared to other standard treatments as well as lower withdrawal and drug craving.

Read more at Camurus’ website: https://www.camurus.com/pressreleases/

Latest news

2021-11-03

Stefan Persson – New President and CEO

Martin Jonsson´s successor as President and CEO of the Sandberg Development Group has now been appointed and it is w…

Read more

2021-07-15

Camurus Interim Report for the second quarter 2021

Today, Camurus' interim report for the second quarter 2021 was published. "It was a positive second quarter with sig…

Read more

2021-05-20

Camurus receives Carnegie Sustainability Award 2021

Camurus has been awarded with the Carnegie Sustainability Award 2021 in the category small-cap, presented at the Car…

Read more

2021-04-21

Camurus Annual Report for 2020

Camurus Annual Report for 2020 is now available at the company's website.

Read more

2021-02-19

Granuldisk finalist at Malmö Näringslivsgala

Granuldisk was selected as one of the finalists presented by Malmö Näringslivsgala, a business gala for companies lo…

Read more